After a shortage due to production delays, Finacea®(azelaic acid) Foam, 15% is now available, LEO Pharma says. Finacea Foam is the first and only prescription foam FDA approved for the treatment of rosacea. It is a light water-based (hydrophilic) foam that is alcohol-free and fragrance free.

LEO Pharma acquired Finacea in its 2018 acquisition of Bayer’s prescription dermatology business in the United States. However, beginning in mid-2019, a manufacturing delay had suspended product supply. The company fully investigated the root cause and supply has been restored.

“We are pleased to bring Finacea Foam back on the market as an option for healthcare providers and their patients in the treatment and management of mild-to-moderate rosacea,” says Christopher Posner, President and CEO, LEO Pharma Inc. “People affected by rosacea are challenged by a chronic condition that affects the face, with symptoms including raised spots and pimple-like bumps. Helping patients is our mission at LEO Pharma, and we remain committed to supporting the medical dermatology community.”

Finacea Foam is again available at the local and specialty pharmacy levels; patients with further questions about local availability should contact their pharmacy for more information. 



Through LEO Pharma Connect, eligible commercially insured patients may pay as little as $20 for each Finacea Foam prescription co-pay. Certain restrictions apply, and patients are not eligible if enrolled or participating in any state or federally funded health care program.